People
The company reported overall positive results for both efficacy and safety, although not a lot of details were released on the actual data.
With its proprietary, top-down view of the immune system and purportedly the world’s largest proprietary data devoted to clinical immunologics, it aims to catalyze significant improvements in disease detection, diagnosis and treatment.
Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.
With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentysis®.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
Earlier this week, Sanofi’s chief executive officer Paul Hudson indicated that the U.S. would have first access to its COVID-19 vaccine because of the significant financial support it is receiving from the U.S. government.
PRESS RELEASES